tbuckley/cabot-search huggingface dataset:
Prognostic factors, symptoms, and consequences of electrolyte imbalances in patients who suffered from cancer.
Authors: Pawel Bryniarski
Journal: Journal of Clinical Oncology (2017)

74 Background: Dyselectrolytemia is a common problem in patients with terminal cancer. It worsens the quality of life and increases the amount of complications. The aim of our study was to determine factors connected with dyselectrolytemia in patients with terminal cancer. Methods: 310 terminal cancer patients admitted to Palliative Care Unit were retrospectively analyzed. Detailed physical examination, medical history and laboratory parameters were taken upon admission. Univariate and multivariate logistic regression analysis were used to determine possible predictors, symptoms and consequences of dyselectrolytemia. Results: On admission 67,74% of patients had dyselectrolytemia. They were more frequently admitted to hospital from Emergency Department (OR=Odds Ratio=2,879, p=probability value=0,00004), had higher PS scale note (OR=1,627, p=0,0001), were more often cachectic (OR=1,915, p=0,0083), had more often constipation (OR=1,728,p=0,0275), were more often dehydrated (OR=2,609 ,p=0,0007), had lower albumin level (OR=0,909, p=0,00001). They had 275% higher risk of death (OR=2,758, p=0,0001). Multivariate logistic regression analysis after adjustment for possible confounders reviled that admission to hospital from Emergency Department (OR=2,652, p=0,01), higher PS scale note (OR=1,445, p=0,001), opioids administration (OR=2,747, p=0,003), dehydration (OR=1,966 , p=0,038) and higher risk of death (OR=2,432, p=0,002) remained independently associated with dyselectrolytemia. Conclusions: Higher PS scale note, occurrence of dehydration, admission to hospital from Emergency Department and opioids administration are factors associated with dyselectrolytemia. Patients with electrolytes imbalances had 275% higher risk of death. Project "Extension of life and improvement of its quality and reduction of cancer patients' mortality due to proper control of water and electrolyte management and elimination of risk factors for dehydration and dyselectrolytemia." Co-financed by the European Social Fund under the project of the Ministry of Science and Higher Education of Poland entitled "Best of the best! 2.0 ".
Do perioperative antibiotics reduce the risk of surgical-site infections following excision of ulcerated skin cancers? A Critically Appraised Topic
Authors: S.A. Chan, A.G.H. Wernham, N. Stembridge, N. Harper, S. Verykiou, G.A. Fremlin, R.A. Abbott, R.N. Matin
Journal: British Journal of Dermatology (2017)

To review the efficacy of perioperative antibiotics in reducing the risk of surgical‐site infections (SSIs) following excision of ulcerated skin cancers. Study selection, data extraction and analysis were carried out independently by four authors. Only randomized controlled trials (RCTs) reported in the English language were included. RCTs in the English language in which patients received perioperative topical, intralesional or oral antibiotics for dermatological surgery, including Mohs micrographic surgery in general practice, dermatology or plastic surgery departments, were included. The proportion of participants developing SSI following excision of skin lesions. Thirteen RCTs were identified from our literature search of PubMed and Embase, which evaluated SSI following use of topical (n = 5), oral (n = 3), intramuscular (n = 2), intravenous (n = 1) and intralesional antibiotics (n = 2) in dermatological surgery. Two RCTs specifically investigated SSIs in ulcerated skin cancer excisions; one RCT investigated the SSI rate following surgical treatment specifically for ulcerated skin cancers in individuals randomized to topical antibiotics vs. oral cephalexin; and one RCT compared intravenous cefazolin with no antibiotic, demonstrating significant reduction in SSI rates for ulcerated tumours (P = 0·04). The heterogeneity of the RCTs included in this study makes it difficult to make a direct comparison of the outcomes measured. High‐quality evidence demonstrating a beneficial effect of the use of perioperative antibiotics to prevent SSI following excision of ulcerated skin cancers is lacking. In the absence of an evidence base, we propose that a well‐designed multicentre RCT could evaluate the effect of perioperative antibiotics following excision of ulcerated tumours, and potentially reduce inappropriate antibiotic prescription.
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells
Authors: C Botta, M Cucè, M R Pitari, D Caracciolo, A Gullà, E Morelli, C Riillo, L Biamonte, M E Gallo Cantafio, R Prabhala, C Mignogna, A Di Vito, E Altomare, N Amodio, M T Di Martino, P Correale, M Rossi, A Giordano, N C Munshi, P Tagliaferri, P Tassone
Journal: Leukemia (2017)

Dendritic cells (DCs) have a key role in regulating tumor immunity, tumor cell growth and drug resistance. We hypothesized that multiple myeloma (MM) cells might recruit and reprogram DCs to a tumor-permissive phenotype by changes within their microRNA (miRNA) network. By analyzing six different miRNA-profiling data sets, miR-29b was identified as the only miRNA upregulated in normal mature DCs and significantly downregulated in tumor-associated DCs. This finding was validated in primary DCs co-cultured in vitro with MM cell lines and in primary bone marrow DCs from MM patients. In DCs co-cultured with MM cells, enforced expression of miR-29b counteracted pro-inflammatory pathways, including signal transducer and activator of transcription 3 and nuclear factor-κB, and cytokine/chemokine signaling networks, which correlated with patients' adverse prognosis and development of bone disease. Moreover, miR-29b downregulated interleukin-23 in vitro and in the SCID-synth-hu in vivo model, and antagonized a Th17 inflammatory response. All together, these effects translated into strong anti-proliferative activity and reduction of genomic instability of MM cells. Our study demonstrates that MM reprograms the DCs functional phenotype by downregulating miR-29b whose reconstitution impairs DCs ability to sustain MM cell growth and survival. These results underscore miR-29b as an innovative and attractive candidate for miRNA-based immune therapy of MM.
NIH Partners With Drug Makers to Advance Cancer Immunotherapy
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The importance of motivation and emotion for explaining human cognition
Authors: C. Dominik Güss, Dietrich Dörner
Journal: Behavioral and Brain Sciences (2017)

Abstract Lake et al. discuss building blocks of human intelligence that are quite different from those of artificial intelligence. We argue that a theory of human intelligence has to incorporate human motivations and emotions. The interaction of motivation, emotion, and cognition is the real strength of human intelligence and distinguishes it from artificial intelligence.
Proton pump inhibitors and the risk for gastric cancer: possible confounding by serum vitamin B<sub><sub>12</sub></sub>
Authors: Itai Gueta, Hillel Halkin, Noa Markovits, Ronen Loebstein
Journal: Gut (2017)

We read with interest the article by Cheung et al 1 reporting an increased risk of gastric cancer with long-term exposure to proton pump inhibitors (PPI) following Helicobacter pylori (HP) eradication. Several recent reports and a meta-analysis have also demonstrated this association.2 3 The present study, using strict exclusion criteria, was able to adjust for the confounding effect of previous HP infection and eradication, demonstrating a PPI exposure-dependent escalating risk for non-cardia gastric cancer (NCGC) in previously infected patients. The authors suggest that the profound acid suppression by PPIs worsens the atrophic gastritis induced by HP infection, …
A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).
Authors: Kamalesh Kumar Sankhala, Jean-Yves Blay, Kristen N. Ganjoo, Antoine Italiano, Andrew Bassim Hassan, Tae Min Kim, Vinod Ravi, Philippe Alexandre Cassier, Piotr Rutkowski, Neil Sankar, Ibrahim Qazi, Robert S. Sikorski, Helen Collins, Charlie Zhang, Ellyn Shocron, Hans Gelderblom
Journal: Journal of Clinical Oncology (2017)

11078 Background: TGCTis a proliferative, neoplastic joint disease that presents as single nodule (local) or multiple nodules (diffuse D-TGCT). Localized overexpression of colony stimulating factor 1 (CSF1) leads to recruitment of cells expressing the CSF1 receptor (CSF1R), formation of a tumor and inflammation of joints and tendons. Cabira is a monoclonal antibody that inhibits the interaction of the CSF1 and IL-34 ligands with their shared receptor CSF1R. Methods: This Ph 1/2 study is evaluating the safety and efficacy of cabira monotherapy administered IV Q 2wk for 6 mo in patients (pts) with D-TGCT. Eligible pts have inoperable D-TGCT or tumor for which resection would cause unacceptable morbidity. Response is evaluated by MRI, pt reported outcomes, and Ogilvie-Harris (O-H) score (which combines pain, synovitis, range of motion and functional capacity on a scale of 0-12). Results: As of 15 Dec 2016, 22 pts received ≥ 1 dose of cabira at 1, 2 or 4mg/kg. Dose-related exposure increase and significant reduction in target peripheral monocytes were observed. No dose limiting toxicity was identified. 4 mg/kg was chosen for Ph2 based on efficacy, tolerability, and PK. AEs ≥ Gr 2 ( &gt; 10%) were CK elevation 46%, rash and other skin disorders 36%, fatigue 23%, and periorbital/peripheral/face edema 18% each. Gr 3 AEs in ≥ 2 pt were CK elevation (n = 8) and periorbital edema (n = 2). Four drug-related SAEs were reported in 3 pts; hypertension, fever, CRP elevation, and myocarditis. AEs of CK elevation were asymptomatic, improved to &lt; 2X ULN after protocol mandated drug discontinuation and are a known on-target effect of CSF1R inhibition. An amendment was made during Phase 2 to allow dosing with higher CK levels Activity at 4 mg/kg was: 1PR and 1 CK discontinuation in 3 pts in Ph1; 4 PRs in 7 evaluable pts with 6 additional ongoing in Ph2. Positive functional status improvements by O-H score were noted in objective responders (from 2 to 7). Conclusions: The initial demonstration of objective and functional activity supports further development of cabiralizumab in pts with D-TGCT. Updated data from the ongoing Ph2 will be presented. NCT02471716 . Clinical trial information: NCT02471716.
Social-motor experience and perception-action learning bring efficiency to machines
Authors: Ludovic Marin, Ghiles Mostafaoui
Journal: Behavioral and Brain Sciences (2017)

Abstract Lake et al. proposed a way to build machines that learn as fast as people do. This can be possible only if machines follow the human processes: the perception-action loop. People perceive and act to understand new objects or to promote specific behavior to their partners. In return, the object/person provides information that induces another reaction, and so on.
Buurtzorg could work in the UK, but why must it fit into the existing system?
Authors: Michael Bowen
Journal: BMJ (2017)

The piece about the Buurtzorg concept of social and nursing care in the community almost had me misty eyed with hope for the future.1 Few challenges are more important and pressing than resolving this matter in the UK. And we must resolve it or the logistic and financial effects will bulldoze every other health agenda out of the way. …
Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group
Authors: Daan van Rooij, Evdokia Anagnostou, Celso Arango, Guillaume Auzias, Marlene Behrmann, Geraldo F. Busatto, Sara Calderoni, Eileen Daly, Christine Deruelle, Adriana Di Martino, Ilan Dinstein, Fabio Luis Souza Duran, Sarah Durston, Christine Ecker, Damien Fair, Jennifer Fedor, Jackie Fitzgerald, Christine M. Freitag, Louise Gallagher, Ilaria Gori, Shlomi Haar, Liesbeth Hoekstra, Neda Jahanshad, Maria Jalbrzikowski, Joost Janssen, Jason Lerch, Beatriz Luna, Mauricio Moller Martinho, Jane McGrath, Filippo Muratori, Clodagh M. Murphy, Declan G.M. Murphy, Kirsten O’Hearn, Bob Oranje, Mara Parellada, Alessandra Retico, Pedro Rosa, Katya Rubia, Devon Shook, Margot Taylor, Paul M. Thompson, Michela Tosetti, Gregory L. Wallace, Fengfeng Zhou, Jan K. Buitelaar
Journal: American Journal of Psychiatry (2017)

Neuroimaging studies show structural differences in both cortical and subcortical brain regions in children and adults with autism spectrum disorder (ASD) compared with healthy subjects. Findings are inconsistent, however, and it is unclear how differences develop across the lifespan. The authors investigated brain morphometry differences between individuals with ASD and healthy subjects, cross-sectionally across the lifespan, in a large multinational sample from the Enhancing Neuroimaging Genetics Through Meta-Analysis (ENIGMA) ASD working group.The sample comprised 1,571 patients with ASD and 1,651 healthy control subjects (age range, 2-64 years) from 49 participating sites. MRI scans were preprocessed at individual sites with a harmonized protocol based on a validated automated-segmentation software program. Mega-analyses were used to test for case-control differences in subcortical volumes, cortical thickness, and surface area. Development of brain morphometry over the lifespan was modeled using a fractional polynomial approach.The case-control mega-analysis demonstrated that ASD was associated with smaller subcortical volumes of the pallidum, putamen, amygdala, and nucleus accumbens (effect sizes [Cohen's d], 0.13 to -0.13), as well as increased cortical thickness in the frontal cortex and decreased thickness in the temporal cortex (effect sizes, -0.21 to 0.20). Analyses of age effects indicate that the development of cortical thickness is altered in ASD, with the largest differences occurring around adolescence. No age-by-ASD interactions were observed in the subcortical partitions.The ENIGMA ASD working group provides the largest study of brain morphometry differences in ASD to date, using a well-established, validated, publicly available analysis pipeline. ASD patients showed altered morphometry in the cognitive and affective parts of the striatum, frontal cortex, and temporal cortex. Complex developmental trajectories were observed for the different regions, with a developmental peak around adolescence. These findings suggest an interplay in the abnormal development of the striatal, frontal, and temporal regions in ASD across the lifespan.
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
Authors: Alexander Gerbes, Fabien Zoulim, Herbert Tilg, Jean-François Dufour, Jordi Bruix, Valérie Paradis, Riad Salem, Markus Peck-Radosavljevic, Peter R Galle, Tim F Greten, Jean-Charles Nault, Matias A Avila
Journal: Gut (2017)

Hepatocellular carcinoma (HCC) ranks number three among the most frequent causes of death from solid tumors worldwide. With obesity and fatty liver diseases as risk factors on the rise, HCC represents an ever increasing challenge. While there is still no curative treatment for most patients numerous novel drugs have been proposed, but most ultimately failed in phase III trials. This manuscript targets therapeutic advances and most burning issues. Expert key point summaries and urgent research agenda are provided regarding risk factors, including microbiota, need for prognostic and predictive biomarkers and the equivocal role of liver biopsy. Therapeutic topics highlighted are locoregional techniques, combination therapies and the potential of immunotherapy. Finally the manuscript provides a critical evaluation of novel targets and strategies for personalized treatment of HCC.
P2.07-008 Does PD-L1 Expression of the Archive Surgical Specimen of Primary Tumor Predict the Sensitivity of Recurrence to Nivolumab in Patients with NSCLC?
Authors: Y. Shiina, H. Suzuki, Y. Sakairi, H. Tamura, H. Wada, T. Fujiwara, T. Nakajima, M. Chiyo, M. Ota, S. Ota, Y. Nakatani, I. Yoshino
Journal: Journal of Thoracic Oncology (2017)
Systemic and Airway Inflammation after Exposure to Fumes from Military Small Arms
Authors: Liv I. B. Sikkeland, Anne K. Borander, Øyvind A. Voie, Hans C. D. Aass, Reidun Øvstebø, Pål Aukrust, Kjetil Longva, Neil E. Alexis, Johny Kongerud, Thor Ueland
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Sikkeland, Liv Ingunn Bjoner; Borander, Anne Katrine; Voie, Oyvind Albert; Aass, Hans Christian Dalsbotten; Ovstebo, Reidun; Aukrust, Pal; Longva, Kjetil Sager; Alexis, Neil E.; Kongerud, Johny; Ueland, Thor. 
Systemic and Airway Inflammation After Exposure to Fumes from Military Small Arms. American Journal of Respiratory and Critical Care Medicine 2018 ;Volum 197.(10) s. 1349-1353
Chancellor’s £2.8bn NHS cash pledge will not ease pressures, leaders warn
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The NHS in England will receive an additional £2.8bn (€3.16bn; $3.72bn) from the government over the next two years to invest in frontline services, the chancellor of the exchequer has announced.

In his annual autumn budget on 22 November, Philip Hammond also pledged a further £3.5bn of new capital funding for the NHS in England to support new buildings and infrastructure, and he committed to funding pay awards for NHS staff on the Agenda for Change contract, including nurses, once an increase is agreed between the unions and the government.

Healthcare leaders said that the extra frontline cash was welcome but that it fell short of what the NHS required to maintain levels of care. Before the budget Simon Stevens, NHS England chief executive, and leading experts said that the service required at least £4bn extra a year to maintain performance and to meet current demand.1

In …
From high performance to clinical practice
Authors: Kim Lee-Knight, Christopher Napier
Journal: British Journal of Sports Medicine (2018)

Next October we look forward to welcoming the sports medicine world to Vancouver for Sport Physiotherapy Canada’s 1st Biennial Congress and the 3rd World Congress of Sports Physical Therapy (#SPC2019)! Together, under one roof, many of the world’s top sports medicine clinicians and researchers will take us from high performance to clinical practice.

This conference will nourish and challenge your mind and give you the perfect canvas to be physically active. Vancouver welcomed the world for the 2010 Olympic and Paralympic Winter Games and now we are ready for you! Vancouver has breathtaking scenery that fosters an outdoor active lifestyle. Where the mountains meet the sea, you can ski in the local mountains in the morning and paddle through the inlets in the afternoon. Come for the conference and stay for the city and its surrounds—a run around Stanley Park, a cycle at Whistler, a hike through the North Shore mountains. Or venture to the west coast of Vancouver Island where the edge of the continent falls into the Pacific Ocean. This trip you will never forget. …
Tuberculosis en Austria 1995-99: distribución geográfica y tendencias
Authors: R Strauss, G Fülöp, C Pfeifer
Journal: Eurosurveillance (2003)

En Austria se llevo a cabo un analisis descriptivo de los datos sistematicos de vigilancia de la tuberculosis (TB) para el periodo comprendido entre 1995 y 1999. Los estados federales de Viena y Alta Austria mostraron las incidencias anuales mas elevadas en los cinco anos. Sin embargo, se observo una disminucion generalizada de la incidencia anual en todos los estados federales salvo Carintia (en el que se registro un ligero aumento del 3,2 %). En las ciudades de Viena, Linz, Wels, Salzburgo, Klagenfurt y St-Polten, asi como en las regiones de Tirol oriental, Carintia del sur y Burgenland del sur, la incidencia se situo por encima de la media (g19 casos/100.000 en cada una). El numero de casos por ano y distrito declarados con arreglo al sistema de declaracion obligatoria fue claramente superior a los declarados por los hospitales. Sin embargo, la comparacion de los dos conjuntos de datos mostro una correlacion regional significativa de las tasas de morbilidad estandarizada por edad a nivel de distrito. Los resultados tienden al sesgo de las declaraciones y podrian no reflejar la situacion real de la TB. Las autoridades sanitarias responsables deberian, pues, estudiar los resultados como una 'hipotesis de trabajo' con el fin de revisar el comportamiento de las declaraciones de cada distrito.
P2.07-024 Real-World Data of Nivolumab for Previously Treated Non-Small Cell Lung Cancer Patients in Japan: A Multicenter Retrospective Cohort Study
Authors: D. Fujimoto, H. Yoshioka, Y. Kataoka, Y. Kim, K. Tomii, T. Ishida, M. Hirabayashi, S. Hara, M. Ishitoko, Y. Fukuda, M.H. Hwang, N. Sakai, M. Fukui, H. Nakaji, T. Hirai
Journal: Journal of Thoracic Oncology (2017)
A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination
Authors: Robert D. Junkins, Matthew D. Gallovic, Brandon M. Johnson, Michael A. Collier, Rebekah Watkins-Schulz, Ning Cheng, Clément N. David, Charles E. McGee, Gregory D. Sempowski, Ivo Shterev, Karen McKinnon, Eric M. Bachelder, Kristy M. Ainslie, Jenny P.-Y. Ting
Journal: Journal of Controlled Release (2017)
Abstract 12594: Mmp9 but not Diastolic Function Parameters, Reflect Early Adaptive Cardiac Response in the Metabolic Syndrome
Authors: Angela B Santos, Beatriz G Seligman, Bruce B Duncan, Luis E Rohde, Nadine Clausell, Murilo Foppa
Journal: Circulation (2012)

Introduction: Metabolic syndrome is defined as a combination of several risk factors that are associated with cardiovascular disease. Whether myocardial changes in this syndrome are adaptive conseq...
Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis
Authors: Alexander G G Turpie, Lorenzo G Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Martin van Eickels, Martin Gebel, Walter Ageno
Journal: Blood (2016)